Ferring Pharmaceuticals: Prostatic Neoplasms trials

The registry lists 45 Prostatic Neoplasms studies with Ferring Pharmaceuticals as lead sponsor. 0 are open to participants now and 30 have results posted.

Phase 1 1Phase 2 15Phase 3 21Phase 4 1No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• FIRMAGON® Intensive Drug MonitoringCompletedNCT05181800Results posted
• A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular DiseaseTerminatedNCT02663908Phase 3Results posted
• A Degarelix Trial in Patients With Prostate CancerTerminatedNCT01242748Phase 3Results posted
• A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGONCompletedNCT01234350Results posted
• A Study of Degarelix in Taiwanese Patients With Prostate CancerCompletedNCT01220869Phase 3Results posted
• Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean PatientsCompletedNCT01215513Phase 3Results posted
• Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate CancerCompletedNCT01071915Phase 3Results posted
• A Long Term Safety Study of Degarelix in Patients With Prostate CancerCompletedNCT00967018Phase 3Results posted
• A Trial of Degarelix in Patients With Prostate CancerCompletedNCT00946920Phase 3Results posted
• A Study of Degarelix in Patients With Prostate CancerCompletedNCT00928434Phase 3Results posted
• Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer PatientsCompletedNCT00884273Phase 3Results posted
• Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate CancerCompletedNCT00833248Phase 3Results posted
• Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate CancerTerminatedNCT00831233Phase 3Results posted
• The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate CancerCompletedNCT00819247Phase 2Results posted
• Dose Finding Trial With a New Treatment (Degarelix) for Prostate CancerCompletedNCT00819156Phase 2Results posted
• Investigation of a New Trial Drug (FE200486) in Prostate Cancer PatientsCompletedNCT00818623Phase 2Results posted
• Intermittent Treatment With Degarelix of Patients Suffering From Prostate CancerCompletedNCT00801242Phase 3Results posted
• Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate CancerCompletedNCT00738673Phase 2Results posted
• Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation TherapyCompletedNCT00468286Phase 2Results posted
• A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation TherapyCompletedNCT00451958Phase 3Results posted
• The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate CancerCompletedNCT00295750Phase 3Results posted
• Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate CancerCompletedNCT00268892Phase 2/3Results posted
• Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer PatientsTerminatedNCT00245466Phase 2Results posted
• An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate CancerCompletedNCT00215683Phase 2/3Results posted
• Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer PatientsTerminatedNCT00215657Phase 2Results posted
• Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486CompletedNCT00117949Phase 2Results posted
• Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer PatientsTerminatedNCT00117312Phase 2Results posted
• Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate CancerCompletedNCT00117286Phase 2/3Results posted
• A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate CancerCompletedNCT00116779Phase 2Results posted
• A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate CancerCompletedNCT00116753Phase 2Results posted
• Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With DegarelixCompletedNCT03193645
• Safety and Efficacy of Firmagon® (Degarelix) for InjectionCompletedNCT02886598
• A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate CancerCompletedNCT02726009Phase 4
• A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate CancerCompletedNCT02526784Phase 3
• Pharmacokinetics of Degarelix in Chinese Patients With Prostate CancerCompletedNCT02468284Phase 1
• Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.CompletedNCT02234089
• Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate CancerCompletedNCT02229253
• An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate CancerCompletedNCT02015871Phase 3
• Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in ArgentinaCompletedNCT01861236
• One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese PopulationCompletedNCT01744366Phase 3
• Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy InitiationCompletedNCT01729676
• Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate CancerCompletedNCT01491971Phase 2
• A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate CancerCompletedNCT01215526
• Effectiveness and Safety of Firmagon®CompletedNCT00930319
• Open-Label, Randomised Parallel-Group StudyWithdrawnNCT00728533Phase 3